## Report Information

More information from: https://www.marketresearchfuture.com/reports/bladder-cancer-detection-kit-market-10669

# Bladder Cancer Detection Kit Market Research Report- Forecast till 2030

**Report / Search Code:** MRFR/HC/9185-HCR **Publish Date:** April, 2023

Request Sample

| | | |
|---|---|---|
| **Price** | 1-user PDF : $ 4950.0 | Enterprise PDF : $ 7250.0 |

**Description:**

# Bladder Cancer Detection Kit Market Forecast

The bladder cancer detection kit market is expected to cross ~USD 170 million by 2030 at a CAGR of ~11.40%.

**Bladder Cancer Detection Kit Market Overview:**

Bladder cancer is a common type of cancer in which malignant cells develop in the tissues of the bladder. It often begins in the urothelial cells that line the inside of the bladder. These cells are found in the kidneys and the ureters. Hence, urothelial cancer can occur in the kidneys as well as in ureters.Various manufacturers provide bladder cancer detection kits across the worldwith several products in the R&D phase. For instance, Abbott Laboratories (US) UroVysion bladder cancer kit is marketed globally. This product is a multicolor FISH assay and multitarget that includes staining exfoliated cells in urine with four denatured, fluorescent, centromeric chromosome-enumeration probes.

According to Globocan, the global burden of bladder cancer is significantly high, representing 3.0% of all new cancer diagnoses, 2.1% of all cancer deaths in 2020, and the 11thmost frequently diagnosed cancer worldwide. Hence, the government authorities are keenly observing the development of the products related to bladder cancer detection kits. These authorities have offered guidelines for producing bladder cancer detection kitsthat aid in the early detection of bladder cancer, further reducing the disease burden.

**COVID-19 Analysis of Bladder Cancer Detection Kit Market**

The emergence of the pandemic has affected people across the globe and resulted in the shutdown of operational facilities worldwide. The healthcare industry is facingexceptional encounters during the lockdown phase. The manufacturing units were shut down,which also affected the production of medical products. The supply chain of the medical products was also affected, leading to the decrease in warehouse inventory of the manufactured products.

According to the mortality rates, bladder cancer cases surpass the COVID-19 cases worldwide and can be as high as 52% in 2020. Henceurologists are recommended not to postpone investigation.This resulted in increasing the demand for bladder cancer detection kits currently. This will further drive the growth of the bladder cancer detection kit market during the pandemic and is expected to grow rapidly during the post lockdown period.

**Bladder Cancer Detection Kit Market Dynamics**

**Drivers**

- **Increasing prevalence of bladder cancer**
    - According to the World Cancer Research Fund (WCRF), bladder cancer is diagnosed in about 275,000 people each year, and approximately 108,000 people die due to bladder cancer globally. Moreover, bladder cancer is the sixth most commonly occurring cancer in men and the 17thmost commonly occurring cancer in women worldwide.
    - In 2018, the bladder cancer incidence rates per 100,000 population for men were highest in Greece at40.4%, followed by Lebanon at 40.0% and Denmark at 29.3% of men population. In females, Lebanon showed the highest incidence of 9.4 per 100,000 population. As the prevalence and mortality rate is rising worldwide, the demand for bladder cancer diagnosis is increasing. This further increases the investment in R&D of non-invasive bladder cancer detection products, hence driving the bladder cancer detection kit market growth.

- **Growing geriatric population**
- **Rising investment in R&D activities for the production of bladder cancer detection kits**

**Bladder Cancer Detection Kit Market Restraints**

- **Concerns pertaining to commercialization of the products in the developing countries**

This product is based on new technology,with several products are in the R&D phase. The lack of awareness and demand for non-invasive bladder cancer detection kitshas limited the distribution of bladder cancer detection kits in emerging economies, especially in low- and lower-middle-income countries. The population base and prevalence of bladder cancer are higher in developing countries, but the traditional way of diagnosing it is still highly adopted due to its affordability. Hence, the commercialization of the approved products in these countries is less, which further hampers the growth of the bladder cancer detection kit market.

**Technology Analysis**
The bladder cancer detection kit is anon-invasive urine-based bladder cancer test kit developed in the last fewyears. The Abbott's (US) UroVysionbladder test kit is one of the US FDA-approved non-invasive test kits commonly used for bladder cancer detection in clinical settings.TheCxBladder Detectis a highly sensitive multi-gene urine biomarker test targeting MDK, CDC, IGF, HOXA, and IL8R. These test kits have higher sensitivity than urine cytology, but this technology is more complex and expensive. Since the advantages and sensitivity of these kits are much higher, the urologists recommend this non-invasive detection kit to reduce the use of invasive diagnostic procedures.

**Bladder Cancer Detection Kit Market Segment Overview**

**By Technology**

- **Fluorescence In Situ Hybridization (FISH):**This technique is used in the field of urology to provide a non-invasive diagnostic application to replace cystoscopy. This is the special urine examination method used to detects genetic alterations of the urothelial cells found in the urine using fluorescent directlabeled DNA probes.UroVysion is one of the products based onthe FISH techniqueoffered by Abbott Laboratories (US).
- **Enzyme-Linked Immunosorbent Assay (ELISA):**This technology is used to detect minichromosome maintenance complex component 5 (MCM5) protein, as MCM5 acts as a biomarker for cancer. This can also detect bladder cancer in people with symptoms associated with malignancy, including blood in the urine.
- **Others**

**By End User**

- **Hospitals& Clinics:**The advancement in the hospital infrastructure across the globe is driving the bladder cancer detection kit market. The investors are capitalizing on the bladder cancer domain by establishing hospitals for cancer diagnosis and treatment.
- **Diagnostic Centre:**The demand for bladder cancer diagnosis is increasing, owing to the immediate diagnosisof the patient condition and no long queues. Such procedures are economicalat the diagnostic centers.
- **Others**

**Bladder Cancer Detection Kit Market Regional Analysis**

- **North America**

**Rising prevalence of bladder cancer across the region is driving the North American bladder cancer detection kit market**

North Americaholds the largest bladder cancer detection kit market share in 2020, owing to the rising prevalence of bladder cancer. According to the American Cancer Society, about 83,730 new cases of bladder cancer and approximately 17,200 deaths from bladder cancer occurred in the US in 2020. Moreover,well-established research organizations engaged in product development, the availability of innovative diagnostic products, and the presence of major players in the region further fuel the growth of the bladder cancer detection kit market. The prominent players are involved in expanding their operational facilities across the region, engaging in collaborations and partnerships, and launching new products for business growth.

- **Asia-Pacific**

**Rising prevalence of bladder cancer in aging populations fueling the Asia-Pacific bladder cancer detection kit market**

Bladder cancer is primarily observed among older people aged between 65 to 85 years. In Japan, according to Globocan, it is estimated that about 37,000 new cases of bladder cancer are diagnosed per year and about 11,000 mortality per year from bladder cancer, andthe aging population is the main reason behind the surge of bladder cancer. In China, the aging population is expanding every year,and bladder cancer rates are increasing subsequently. It is estimated that the incidence rate of bladder cancer above age 65 is 49.6 per 100,000 people. Hence the rising rate of bladder cancer among elderly individuals and the increasing population of aging people in Asia-Pacific helps to drive the growth of the bladder cancer detection kit market.

**Bladder Cancer Detection Kit Market- Competitive Landscape**

The bladder cancer detection kit market is profitable, both for existing players as well as new entrants. Our analysis revealed that market players adopt different strategies and innovative R&D techniques to expand their business and secure their position in the bladder cancer detection kit market. Abbott Laboratories'(US)UroVysion bladder cancer kit (UroVysion Kit) was the first FDA-approved product distributed across the world.This product is designed to identify aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus through the FISH technology in urine specimens.Various other players also offer bladder cancer detection kits such as Cepheid's Xpert Bladder Cancer Detection, CxBladder Detect, a non-invasive, urine-based test thatoffers accurate results, is easier to use, and clinically validated in laboratory settings. Therefore, the industry players are coming up with various business strategies to increase their market presence. The companies invest in R&D activities to expand their product portfolio, further driving the bladder cancer detection kit market. In addition, the bladder cancer detection kit market players are adopting various strategies such as mergers &acquisitions, contractual agreements, new product launches, increasing investmentsin R&D, and partnering with other players to expand their global footprint.

**List of Key Companies Covered in Bladder Cancer Detection Kit Market Report**

- Abbott Laboratories (US)
- Xiamen Biotime Biotechnology (China)
- Exact Sciences (US)
- Hubei Jinjian Biology (China)
- Nanjing Liming Bio-products Co., Ltd (China)
- Abingdon Health (UK)
- Ameritek, Inc. (US)
- Alfa Scientific Designs (US)
- NanoEnTek Inc. (South Korea)
- Diagnosis S.A. (Spain)
- Xiamen Boson Biotech Co., Ltd (China)

**Recent Developments**

- In May 2021, KDx Diagnostics (US) collaborated with Cardiff University, Cardiff and Vale University Health Board, or C&VUHB, and CellPathto develop its non-invasive bladder cancer test URO17.
- In March 2021,a France-based OncoDiag company raised USD 3.0 million to commercialize its Urodiag PCR-based diagnostic test for recurrent bladder cancer in France.
- In October 2015, Oxford Gene Technology (OGT) launched its CE-IVD labeled Cytocell Aquarius P16/3c/7c/17c Probe Kit for sale in Europe. It is a ready-to-use and cost-effective fluorescence in situ hybridization (FISH) probe kit used as a non-invasive detection of bladder cancer.

**Report Overview**

The study covers the existing short-term and long-term market effects, as well as helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes bladder cancer detection kit market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID on the bladder cancer detection kit market.

**Bladder Cancer Detection Kit Market Scope of the Report & Segmentation**

**By Technology**

- Fluorescence In Situ Hybridization (FISH)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Others

**By End User**

- Hospitals& Clinics
- Diagnostic Centers

- Others

**Table of Content:**

Contents

LIST OF TABLES

LIST OF FIGURES